Status In progress
Process MTA
ID number 1276

Project Team

Project lead Louise Jafferally

Email enquiries

Evidence Review Group / Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics, University of York


Companies sponsors BTG (Therasphere)
  Sirtex Medical (SIR-Sphere)
  Terumo Europe (QuiremSphere)
Others Department of Health & Social Care
  NHS England
  Welsh Government
Patient carer groups Liver4Life
  British Liver Trust
Professional groups Association of Cancer Physicians
  British Association for the Study of the Liver
  British Society of Interventional Radiology
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
  British Nuclear Medicine Society


Comparator companies Bayer (sorafenib and regorafenib)
  Accord Healthcare (cisplatin, doxorubicin) – (confidentiality agreement not signed)
  Boston Scientific (embozene tandem microspheres) – (confidentiality agreement not signed)
  Eisai (lenvatinib) – (confidentiality agreement not signed)
  Hospira UK (cisplatin) – (confidentiality agreement not signed)
  Medac (doxorubicin) – (confidentiality agreement not signed)
  Merit Medical (HepaSphere Microspheres) – (confidentiality agreement not signed)
  Pfizer (doxorubicin) – (confidentiality agreement not signed)
  PharmaCept (EmboCept S; degradable starch microspheres) – (confidentiality agreement not signed)
  Sandoz (cisplatin) – (confidentiality agreement not signed)
  Seacross Pharmaceuticals (doxorubicin, cisplatin) – (confidentiality agreement not signed)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research
  National Cancer Research Institute


Key events during the development of the guidance:

Date Update
05 December 2019 - 08 January 2020 Appraisal consultation
06 November 2019 Committee meeting: 1
24 September 2019 Assessment report sent for information
08 February 2019 Invitation to participate
04 December 2018 - 18 December 2018 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 1
04 December 2018 Draft scope documents
27 June 2018 Referral
27 June 2018 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance